Japan’s Shionogi & Co. has received U.S. Food and Drug Administration approval for its oral antiviral medication Xocova to prevent COVID-19 following exposure, becoming the first oral therapeutic approved for this preventive indication.
This regulatory milestone represents a breakthrough in COVID-19 prevention approaches, with potential to decrease transmission in household environments and high-risk scenarios involving exposure.
Key Takeaways
- First oral COVID-19 prevention drug approved by FDA
- Reduces symptomatic COVID-19 risk by 67% in clinical trials
- Targets post-exposure prophylaxis within 72 hours of contact
Clinical Trial Success
Regulatory approval stems from Shionogi’s Phase 3 SCORPIO-PEP study results, which established ensitrelvir’s efficacy in preventing COVID-19 among household contacts 1. Within the primary analysis of 2,041 participants, 2.9% of ensitrelvir recipients developed symptomatic COVID-19 compared to 9.0% receiving placebo through day 10.
High-risk populations experienced even more pronounced benefits, with a 76% relative risk reduction for participants having one or more severe disease risk factors. Among high-risk participants, only 2.4% taking ensitrelvir contracted COVID-19 versus 9.9% on placebo 2.
Mechanism and Market Context
The drug functions by inhibiting the main protease of SARS-CoV-2, a critical enzyme for viral replication 3. This approach distinguishes it from current COVID-19 therapies, which are given post-infection after immune responses have initiated.
Ensitrelvir proved effective against various COVID-19 variants, including the prevalent Omicron strain, indicating broad utility as new variants develop. Clinical testing revealed good tolerability, with comparable adverse event frequencies between treatment and placebo arms (15.1% versus 15.5%) 2.
Management Commentary
“Ensitrelvir offers a potential new approach to help prevent COVID-19 after exposure,” said Aeron Hurt, vice president of global medical science at Shionogi. “By preventing COVID-19, people can avoid not only potentially serious consequences of acute disease, but also the risk of exacerbating pre-existing conditions or acquiring new conditions, such as long COVID” 2.
Company leadership highlighted that ensitrelvir reduces COVID-19 development chances by two-thirds, particularly valuable in household environments where transmission risk peaks.
Market Implications
This approval fills a notable void in COVID-19 prevention approaches, especially as vaccination rates decrease and immunity diminishes over time 4. Existing preventive strategies depend mainly on pre-exposure vaccines, while available antivirals target post-infection treatment.
With approval already secured in Japan for COVID-19 treatment and availability in Singapore, Shionogi possesses established manufacturing and distribution infrastructure. The company collaborates with the Medicines Patent Pool to ensure accessibility in low- and middle-income nations 5.
Looking Forward
As COVID-19 continues generating thousands of weekly U.S. hospitalizations and hundreds of deaths, this approval equips healthcare providers with an additional tool for preventing outbreaks in institutional settings, households, and other high-transmission locations 4. The medication’s once-daily dosing over five days provides practical benefits for post-exposure prophylaxis protocols.
Ongoing research may broaden the drug’s applications, with current studies assessing effectiveness in hospitalized patients and pediatric populations aged six to 12 years demonstrating encouraging safety and pharmacokinetic characteristics 4.
Not investment advice. For informational purposes only.
References
1Shionogi & Co., Ltd. (September 3, 2025). “FDA Accepts Shionogi’s Ensitrelvir NDA for Review as the First Oral Therapy for the Prevention of COVID-19 Following Exposure”. Shionogi Global News. Retrieved June 1, 2026.
2Shionogi & Co., Ltd. (May 14, 2026). “New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure”. Shionogi Global News. Retrieved June 1, 2026.
3Unoh, Y., et al. (March 30, 2022). “Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19”. Journal of Medicinal Chemistry. Retrieved June 1, 2026.
4Shionogi & Co., Ltd. (April 1, 2025). “Shionogi Initiates New Drug Application Submission for Ensitrelvir for Post-Exposure Prophylaxis with the U.S. Food and Drug Administration”. Shionogi US News. Retrieved June 1, 2026.
5Shionogi & Co., Ltd. (March 5, 2024). “Shionogi Announces Xocova® (Ensitrelvir Fumaric Acid) Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection”. Shionogi US News. Retrieved June 1, 2026.